Altman L C, Findlay S R, Lopez M, Lukacsko P, Morris R J, Pinnas J L, Ratner P H, Szefler S J, Welch M J
Division of Allergy and Infectious Disease, University of Washington, Seattle.
Chest. 1992 May;101(5):1250-6. doi: 10.1378/chest.101.5.1250.
A study to assess the effect of the long-term use of triamcinolone acetonide (TA) on adrenal function was conducted with 143 male and female patients with asthma who were randomly assigned to receive 800, 1200, or 1,600 micrograms of TA daily for six months. Adrenal function was assessed prior to treatment and after two weeks and one, three, and six months of TA use. The effect of TA was evaluated by measuring plasma cortisol levels just prior to and 30 min after a bolus IV injection of 0.25 mg cosyntropin. Adrenal suppression was assumed if the plasma concentration of cortisol did not increase by at least 7 micrograms/dl from the prestimulation value, and remained below 18 micrograms/dl 30 min after the cosyntropin injection. Urine collected for 24 h prior to each cosyntropin stimulation was assayed for free cortisol and related metabolites to confirm suppression. Although all treatment regimens caused some reduction in the 24-h excretion of corticosteroid products, none of the mean values was below the normal ranges. The mean data indicate that TA had no significant effect on adrenal function at any dose or at any time for the patients overall. Individually, three patients exhibited some reduction in adrenal function.
一项针对143例哮喘患者(包括男性和女性)的研究评估了长期使用曲安奈德(TA)对肾上腺功能的影响,这些患者被随机分配,每天接受800、1200或1600微克的TA治疗,为期6个月。在治疗前以及使用TA两周后、1个月、3个月和6个月后评估肾上腺功能。通过在静脉推注0.25毫克促肾上腺皮质激素之前和之后30分钟测量血浆皮质醇水平来评估TA的效果。如果皮质醇的血浆浓度在促肾上腺皮质激素注射后30分钟内未比刺激前的值至少增加7微克/分升,且仍低于18微克/分升,则认为存在肾上腺抑制。在每次促肾上腺皮质激素刺激前收集24小时尿液,检测游离皮质醇和相关代谢产物以确认抑制情况。尽管所有治疗方案均导致皮质类固醇产物的24小时排泄量有所减少,但所有平均值均未低于正常范围。平均数据表明,总体而言,TA对任何剂量或任何时间的患者肾上腺功能均无显著影响。个别情况下,有3例患者的肾上腺功能出现了一定程度的降低。